TCGA-CN-6020-01A-11R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.046803653
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.530
- IL6_JAK_STAT3_SIGNALING+0.480
- ANGIOGENESIS+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- INFLAMMATORY_RESPONSE+0.450
- TGF_BETA_SIGNALING+0.450
- CHOLESTEROL_HOMEOSTASIS+0.410
- KRAS_SIGNALING_UP+0.410
- COAGULATION+0.380
- NOTCH_SIGNALING+0.340
Top 10 suppressed
- E2F_TARGETS-0.260
- DNA_REPAIR-0.220
- MYC_TARGETS_V1-0.190
- WNT_BETA_CATENIN_SIGNALING-0.110
- FATTY_ACID_METABOLISM-0.070
- SPERMATOGENESIS-0.070
- BILE_ACID_METABOLISM-0.040
- MYC_TARGETS_V2-0.010
- G2M_CHECKPOINT+0.010
- PEROXISOME+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320076 | — | — | 0.915 |
| 2 | s_150324_4b | EPN | Posterior Fossa EPN | 0.907 |
| 3 | MNG281 | — | — | 0.904 |
| 4 | BS_WRHDP7WF | EPN | Posterior Fossa EPN | 0.900 |
| 5 | EPT0509 | EPN | EPN Tumor | 0.880 |
| 6 | 22DF9124-1DD5-4ED9-874E-2AB05A94F17E | — | — | 0.880 |
| 7 | BS_WRHDP7WF | Posterior Fossa Ependymoma | — | 0.878 |
| 8 | SRR10900576 | — | — | 0.877 |
| 9 | BS_593HEWBF | Ganglioglioma | — | 0.875 |
| 10 | BS_N1E0H8YQ | low-grade glioma | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.320 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |